Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages.

Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC, Hsieh SL.

J Immunol. 2012 Mar 1;188(5):2464-71. doi: 10.4049/jimmunol.1101101. Epub 2012 Jan 27.

2.

Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion.

Cheng CP, Sytwu HK, Chang DM.

J Rheumatol. 2011 Dec;38(12):2522-35. doi: 10.3899/jrheum.110245. Epub 2011 Sep 1.

PMID:
21885501
3.

Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.

Lin WW, Hsieh SL.

Biochem Pharmacol. 2011 Apr 1;81(7):838-47. doi: 10.1016/j.bcp.2011.01.011. Epub 2011 Feb 2. Review.

PMID:
21295012
4.

Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.

Melichar B, Fridrichová P, Tomsová M, Malírová E.

Eur J Gynaecol Oncol. 2009;30(3):323-5.

PMID:
19697632
6.

The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid.

Mueller AM, Pedré X, Killian S, David M, Steinbrecher A.

J Neuroimmunol. 2009 Apr 30;209(1-2):57-64. doi: 10.1016/j.jneuroim.2009.01.024. Epub 2009 Mar 6.

PMID:
19269042
7.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
8.

Decoy receptor 3 is a prognostic factor in renal cell cancer.

Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W.

Neoplasia. 2008 Oct;10(10):1049-56.

9.

Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.

Connor JP, Felder M.

Gynecol Oncol. 2008 Nov;111(2):330-5. doi: 10.1016/j.ygyno.2008.07.012. Epub 2008 Aug 23.

PMID:
18723214
10.

Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.

Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL.

Blood. 2008 May 15;111(10):5054-63. doi: 10.1182/blood-2007-12-130609. Epub 2008 Mar 18.

11.

Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).

You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL.

Blood. 2008 Feb 1;111(3):1480-8. Epub 2007 Nov 15.

12.

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.

PMID:
17490732
13.

Shift syndecan-2 from RACK1 to caveolin-2 upon transformation with oncogenic ras.

Huang JW, Chuang NN.

Biochem Biophys Res Commun. 2006 Nov 10;350(1):227-32. Epub 2006 Sep 18.

PMID:
16997272
14.

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.

Foulkes WD.

Fam Cancer. 2006;5(2):135-42. Review.

PMID:
16736282
15.
16.

The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion.

Chang YC, Chan YH, Jackson DG, Hsieh SL.

J Immunol. 2006 Jan 1;176(1):173-80.

17.
18.

Attenuation of Th1 response in decoy receptor 3 transgenic mice.

Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL.

J Immunol. 2005 Oct 15;175(8):5135-45.

19.

Syndecan-2.

Essner JJ, Chen E, Ekker SC.

Int J Biochem Cell Biol. 2006 Feb;38(2):152-6. Epub 2005 Sep 15. Review.

PMID:
16198615
20.

CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray.

Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD.

Int J Cancer. 2006 Mar 15;118(6):1460-4.

Supplemental Content

Support Center